Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens
Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer. A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2001-06, Vol.19 (27), p.3652-3660 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3660 |
|---|---|
| container_issue | 27 |
| container_start_page | 3652 |
| container_title | Vaccine |
| container_volume | 19 |
| creator | van der Burg, S.H. Kwappenberg, K.M.C. O'Neill, T. Brandt, R.M.P. Melief, C.J.M. Hickling, J.K. Offringa, R. |
| description | Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer. A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-helper cells and antibodies in a pre-clinical mouse model. These immune responses effectively prevented outgrowth of HPV16-positive tumour cells in a prophylactic setting as well as in a minimal residual disease setting. CTL immunity was optimally induced when TA-CIN was employed in heterologous prime-boost regimens in combination with TA-HPV, a clinical grade vaccinia-based vaccine. These data provide a scientific basis for the use of TA-CIN, alone or in combination with TA-HPV in future human trials. |
| doi_str_mv | 10.1016/S0264-410X(01)00086-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18072363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X0100086X</els_id><sourcerecordid>18072363</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-d8341ee4c8edfbe8e1e9a611afee3a7c4474467eb6e24bb436878668b58e27f3</originalsourceid><addsrcrecordid>eNqFkd1u1DAQhS0EokvhEUC-AYHUgCd2HOcKVauFVlpBJVZo7yzHmbRGid3a2Ur7Gn3ien-gl1zZHn0zc3wOIW-BfQYG8ssvVkpRCGDrjww-McaULNbPyAxUzYuyAvWczP4hJ-RVSn8yVHFoXpITAN5U0DQz8nAVsbCD886agSbT47SlxncU-z6X7JaGnq7Oi_nljzNqaEQbxtZ54yd6cfUbJF2WC7moab9JLnh6G8OEztN7Y63zeEbz_SaMYQjXYZP2g29wwvi3cBvdiEUbQpry7Ov88Ok1edGbIeGb43lKVt8Wq_lFsfz5_XJ-viysUGoqOsUFIAqrsOtbVAjYGAmQv4Dc1FaIWghZYyuxFG0ruFS1klK1lcKy7vkp-XAYmzXfbTBNenTJ4jAYj1maBsXqkkueweoA2hhSitjrnWoTtxqY3mWh91nondGagd5node5791xwaYdsXvqOpqfgfdHwKTsfh-Nty49cQIqXrMd9_XAYXbj3mHUyTr0FjuX85h0F9x_pDwCZRuncw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18072363</pqid></control><display><type>article</type><title>Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van der Burg, S.H. ; Kwappenberg, K.M.C. ; O'Neill, T. ; Brandt, R.M.P. ; Melief, C.J.M. ; Hickling, J.K. ; Offringa, R.</creator><creatorcontrib>van der Burg, S.H. ; Kwappenberg, K.M.C. ; O'Neill, T. ; Brandt, R.M.P. ; Melief, C.J.M. ; Hickling, J.K. ; Offringa, R.</creatorcontrib><description>Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer. A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-helper cells and antibodies in a pre-clinical mouse model. These immune responses effectively prevented outgrowth of HPV16-positive tumour cells in a prophylactic setting as well as in a minimal residual disease setting. CTL immunity was optimally induced when TA-CIN was employed in heterologous prime-boost regimens in combination with TA-HPV, a clinical grade vaccinia-based vaccine. These data provide a scientific basis for the use of TA-CIN, alone or in combination with TA-HPV in future human trials.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(01)00086-X</identifier><identifier>PMID: 11395199</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject><![CDATA[AE6 protein ; AE7 protein ; Animals ; Antigens, Neoplasm - administration & dosage ; Antigens, Neoplasm - immunology ; Antigens, Neoplasm - therapeutic use ; Antigens, Neoplasm - toxicity ; Antigens, Viral - administration & dosage ; Antigens, Viral - immunology ; Antigens, Viral - therapeutic use ; Antigens, Viral - toxicity ; Biological and medical sciences ; Cancer Vaccines - administration & dosage ; Cancer Vaccines - immunology ; Cancer Vaccines - therapeutic use ; Cancer Vaccines - toxicity ; Capsid - administration & dosage ; Capsid - immunology ; Capsid - therapeutic use ; Capsid - toxicity ; Capsid Proteins ; Cell Line ; Cell Line, Transformed ; Cervical intraepithelial neoplasia ; Cervical Intraepithelial Neoplasia - prevention & control ; Cervical Intraepithelial Neoplasia - therapy ; Cervical Intraepithelial Neoplasia - virology ; Drug Evaluation, Preclinical ; E6 protein ; E7 protein ; Epidemiology. Vaccinations ; Fundamental and applied biological sciences. Psychology ; General aspects ; HPV ; Human papillomavirus ; human papillomavirus 16 ; Immunotherapy ; Infectious diseases ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Microbiology ; Oncogene Proteins, Viral - administration & dosage ; Oncogene Proteins, Viral - immunology ; Oncogene Proteins, Viral - therapeutic use ; Oncogene Proteins, Viral - toxicity ; Papillomaviridae - immunology ; Papillomavirus E7 Proteins ; Recombinant Fusion Proteins - administration & dosage ; Recombinant Fusion Proteins - immunology ; Recombinant Fusion Proteins - therapeutic use ; Recombinant Fusion Proteins - toxicity ; TA-CIN vaccine ; Vaccines, Acellular - administration & dosage ; Vaccines, Acellular - immunology ; Vaccines, Acellular - therapeutic use ; Vaccines, Acellular - toxicity ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Virology]]></subject><ispartof>Vaccine, 2001-06, Vol.19 (27), p.3652-3660</ispartof><rights>2001 Elsevier Science Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-d8341ee4c8edfbe8e1e9a611afee3a7c4474467eb6e24bb436878668b58e27f3</citedby><cites>FETCH-LOGICAL-c488t-d8341ee4c8edfbe8e1e9a611afee3a7c4474467eb6e24bb436878668b58e27f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X0100086X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14153709$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11395199$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Burg, S.H.</creatorcontrib><creatorcontrib>Kwappenberg, K.M.C.</creatorcontrib><creatorcontrib>O'Neill, T.</creatorcontrib><creatorcontrib>Brandt, R.M.P.</creatorcontrib><creatorcontrib>Melief, C.J.M.</creatorcontrib><creatorcontrib>Hickling, J.K.</creatorcontrib><creatorcontrib>Offringa, R.</creatorcontrib><title>Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer. A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-helper cells and antibodies in a pre-clinical mouse model. These immune responses effectively prevented outgrowth of HPV16-positive tumour cells in a prophylactic setting as well as in a minimal residual disease setting. CTL immunity was optimally induced when TA-CIN was employed in heterologous prime-boost regimens in combination with TA-HPV, a clinical grade vaccinia-based vaccine. These data provide a scientific basis for the use of TA-CIN, alone or in combination with TA-HPV in future human trials.</description><subject>AE6 protein</subject><subject>AE7 protein</subject><subject>Animals</subject><subject>Antigens, Neoplasm - administration & dosage</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antigens, Neoplasm - therapeutic use</subject><subject>Antigens, Neoplasm - toxicity</subject><subject>Antigens, Viral - administration & dosage</subject><subject>Antigens, Viral - immunology</subject><subject>Antigens, Viral - therapeutic use</subject><subject>Antigens, Viral - toxicity</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - administration & dosage</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Cancer Vaccines - toxicity</subject><subject>Capsid - administration & dosage</subject><subject>Capsid - immunology</subject><subject>Capsid - therapeutic use</subject><subject>Capsid - toxicity</subject><subject>Capsid Proteins</subject><subject>Cell Line</subject><subject>Cell Line, Transformed</subject><subject>Cervical intraepithelial neoplasia</subject><subject>Cervical Intraepithelial Neoplasia - prevention & control</subject><subject>Cervical Intraepithelial Neoplasia - therapy</subject><subject>Cervical Intraepithelial Neoplasia - virology</subject><subject>Drug Evaluation, Preclinical</subject><subject>E6 protein</subject><subject>E7 protein</subject><subject>Epidemiology. Vaccinations</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General aspects</subject><subject>HPV</subject><subject>Human papillomavirus</subject><subject>human papillomavirus 16</subject><subject>Immunotherapy</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microbiology</subject><subject>Oncogene Proteins, Viral - administration & dosage</subject><subject>Oncogene Proteins, Viral - immunology</subject><subject>Oncogene Proteins, Viral - therapeutic use</subject><subject>Oncogene Proteins, Viral - toxicity</subject><subject>Papillomaviridae - immunology</subject><subject>Papillomavirus E7 Proteins</subject><subject>Recombinant Fusion Proteins - administration & dosage</subject><subject>Recombinant Fusion Proteins - immunology</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Recombinant Fusion Proteins - toxicity</subject><subject>TA-CIN vaccine</subject><subject>Vaccines, Acellular - administration & dosage</subject><subject>Vaccines, Acellular - immunology</subject><subject>Vaccines, Acellular - therapeutic use</subject><subject>Vaccines, Acellular - toxicity</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkd1u1DAQhS0EokvhEUC-AYHUgCd2HOcKVauFVlpBJVZo7yzHmbRGid3a2Ur7Gn3ien-gl1zZHn0zc3wOIW-BfQYG8ssvVkpRCGDrjww-McaULNbPyAxUzYuyAvWczP4hJ-RVSn8yVHFoXpITAN5U0DQz8nAVsbCD886agSbT47SlxncU-z6X7JaGnq7Oi_nljzNqaEQbxtZ54yd6cfUbJF2WC7moab9JLnh6G8OEztN7Y63zeEbz_SaMYQjXYZP2g29wwvi3cBvdiEUbQpry7Ov88Ok1edGbIeGb43lKVt8Wq_lFsfz5_XJ-viysUGoqOsUFIAqrsOtbVAjYGAmQv4Dc1FaIWghZYyuxFG0ruFS1klK1lcKy7vkp-XAYmzXfbTBNenTJ4jAYj1maBsXqkkueweoA2hhSitjrnWoTtxqY3mWh91nondGagd5node5791xwaYdsXvqOpqfgfdHwKTsfh-Nty49cQIqXrMd9_XAYXbj3mHUyTr0FjuX85h0F9x_pDwCZRuncw</recordid><startdate>20010614</startdate><enddate>20010614</enddate><creator>van der Burg, S.H.</creator><creator>Kwappenberg, K.M.C.</creator><creator>O'Neill, T.</creator><creator>Brandt, R.M.P.</creator><creator>Melief, C.J.M.</creator><creator>Hickling, J.K.</creator><creator>Offringa, R.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20010614</creationdate><title>Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens</title><author>van der Burg, S.H. ; Kwappenberg, K.M.C. ; O'Neill, T. ; Brandt, R.M.P. ; Melief, C.J.M. ; Hickling, J.K. ; Offringa, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-d8341ee4c8edfbe8e1e9a611afee3a7c4474467eb6e24bb436878668b58e27f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>AE6 protein</topic><topic>AE7 protein</topic><topic>Animals</topic><topic>Antigens, Neoplasm - administration & dosage</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antigens, Neoplasm - therapeutic use</topic><topic>Antigens, Neoplasm - toxicity</topic><topic>Antigens, Viral - administration & dosage</topic><topic>Antigens, Viral - immunology</topic><topic>Antigens, Viral - therapeutic use</topic><topic>Antigens, Viral - toxicity</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - administration & dosage</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Cancer Vaccines - toxicity</topic><topic>Capsid - administration & dosage</topic><topic>Capsid - immunology</topic><topic>Capsid - therapeutic use</topic><topic>Capsid - toxicity</topic><topic>Capsid Proteins</topic><topic>Cell Line</topic><topic>Cell Line, Transformed</topic><topic>Cervical intraepithelial neoplasia</topic><topic>Cervical Intraepithelial Neoplasia - prevention & control</topic><topic>Cervical Intraepithelial Neoplasia - therapy</topic><topic>Cervical Intraepithelial Neoplasia - virology</topic><topic>Drug Evaluation, Preclinical</topic><topic>E6 protein</topic><topic>E7 protein</topic><topic>Epidemiology. Vaccinations</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General aspects</topic><topic>HPV</topic><topic>Human papillomavirus</topic><topic>human papillomavirus 16</topic><topic>Immunotherapy</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microbiology</topic><topic>Oncogene Proteins, Viral - administration & dosage</topic><topic>Oncogene Proteins, Viral - immunology</topic><topic>Oncogene Proteins, Viral - therapeutic use</topic><topic>Oncogene Proteins, Viral - toxicity</topic><topic>Papillomaviridae - immunology</topic><topic>Papillomavirus E7 Proteins</topic><topic>Recombinant Fusion Proteins - administration & dosage</topic><topic>Recombinant Fusion Proteins - immunology</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Recombinant Fusion Proteins - toxicity</topic><topic>TA-CIN vaccine</topic><topic>Vaccines, Acellular - administration & dosage</topic><topic>Vaccines, Acellular - immunology</topic><topic>Vaccines, Acellular - therapeutic use</topic><topic>Vaccines, Acellular - toxicity</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Burg, S.H.</creatorcontrib><creatorcontrib>Kwappenberg, K.M.C.</creatorcontrib><creatorcontrib>O'Neill, T.</creatorcontrib><creatorcontrib>Brandt, R.M.P.</creatorcontrib><creatorcontrib>Melief, C.J.M.</creatorcontrib><creatorcontrib>Hickling, J.K.</creatorcontrib><creatorcontrib>Offringa, R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Burg, S.H.</au><au>Kwappenberg, K.M.C.</au><au>O'Neill, T.</au><au>Brandt, R.M.P.</au><au>Melief, C.J.M.</au><au>Hickling, J.K.</au><au>Offringa, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2001-06-14</date><risdate>2001</risdate><volume>19</volume><issue>27</issue><spage>3652</spage><epage>3660</epage><pages>3652-3660</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Human papillomavirus (HPV) E6 and E7 oncoproteins are attractive targets for T-cell-based immunotherapy of cervical intraepithelial neoplasia (CIN) and cancer. A newly designed vaccine, comprising the HPV16 L2, E6 and E7 as a single fusion protein (TA-CIN), was shown to elicit HPV16-specific CTL, T-helper cells and antibodies in a pre-clinical mouse model. These immune responses effectively prevented outgrowth of HPV16-positive tumour cells in a prophylactic setting as well as in a minimal residual disease setting. CTL immunity was optimally induced when TA-CIN was employed in heterologous prime-boost regimens in combination with TA-HPV, a clinical grade vaccinia-based vaccine. These data provide a scientific basis for the use of TA-CIN, alone or in combination with TA-HPV in future human trials.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>11395199</pmid><doi>10.1016/S0264-410X(01)00086-X</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2001-06, Vol.19 (27), p.3652-3660 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_18072363 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | AE6 protein AE7 protein Animals Antigens, Neoplasm - administration & dosage Antigens, Neoplasm - immunology Antigens, Neoplasm - therapeutic use Antigens, Neoplasm - toxicity Antigens, Viral - administration & dosage Antigens, Viral - immunology Antigens, Viral - therapeutic use Antigens, Viral - toxicity Biological and medical sciences Cancer Vaccines - administration & dosage Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Cancer Vaccines - toxicity Capsid - administration & dosage Capsid - immunology Capsid - therapeutic use Capsid - toxicity Capsid Proteins Cell Line Cell Line, Transformed Cervical intraepithelial neoplasia Cervical Intraepithelial Neoplasia - prevention & control Cervical Intraepithelial Neoplasia - therapy Cervical Intraepithelial Neoplasia - virology Drug Evaluation, Preclinical E6 protein E7 protein Epidemiology. Vaccinations Fundamental and applied biological sciences. Psychology General aspects HPV Human papillomavirus human papillomavirus 16 Immunotherapy Infectious diseases Medical sciences Mice Mice, Inbred C57BL Microbiology Oncogene Proteins, Viral - administration & dosage Oncogene Proteins, Viral - immunology Oncogene Proteins, Viral - therapeutic use Oncogene Proteins, Viral - toxicity Papillomaviridae - immunology Papillomavirus E7 Proteins Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - immunology Recombinant Fusion Proteins - therapeutic use Recombinant Fusion Proteins - toxicity TA-CIN vaccine Vaccines, Acellular - administration & dosage Vaccines, Acellular - immunology Vaccines, Acellular - therapeutic use Vaccines, Acellular - toxicity Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Virology |
| title | Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A00%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-clinical%20safety%20and%20efficacy%20of%20TA-CIN,%20a%20recombinant%20HPV16%20L2E6E7%20fusion%20protein%20vaccine,%20in%20homologous%20and%20heterologous%20prime-boost%20regimens&rft.jtitle=Vaccine&rft.au=van%20der%20Burg,%20S.H.&rft.date=2001-06-14&rft.volume=19&rft.issue=27&rft.spage=3652&rft.epage=3660&rft.pages=3652-3660&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(01)00086-X&rft_dat=%3Cproquest_cross%3E18072363%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18072363&rft_id=info:pmid/11395199&rft_els_id=S0264410X0100086X&rfr_iscdi=true |